Cielo Holdings - A new start

* Cielo has conditionally agreed to acquire Curidium Limited ("Curidium")

* The consideration for the acquisition is £3.88m satisfied by the issue new
ordinary shares

* Corporate Synergy Plc has conditionally placed £1.5m for further working
capital purposes

* EGM at 10.00 am on 5 July 2006 to approve resolutions

* Proposed re-admission of the enlarged group to AIM on 6 July 2006

* Reasons for the acquisition

* The proprietary technology, Homomatrix, has led to four product development
programmes to date

* Curidium has a strong management team with expertise in central nervous
system diseases

* The market for targeted medicines provides access to strong growth
opportunities

* Corporate Synergy Plc acted as Nominated Adviser and Broker to the Company.